BRCA2 p.Tyr2624Cys
c.7871A>G · rs431825358 · VCV96860
Computational evidence
| Protein change | ||
| AlphaMissense | 0.6098 | likely pathogenic · top 6% in BRCA2 |
|---|---|---|
| REVEL | 0.903 | moderately pathogenic-leaning |
| ⇒ AlphaMissense and REVEL both call this damaging. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 11 | GERP 2.5, phastCons 1 |
| Regional constraint | o/e 1.03 | unconstrained · MANE · 47 kb · p 0.059 · regional, not allelic |
| Overall | ||
| CADD | 26.7 | PHRED · no single calibrated threshold — expert panels disagree |
ClinVar classifies this uncertain; the computational predictors unanimously lean damaging — a triage signal, not a reclassification
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
gnomAD v4.1 · exomes + genomes| Ancestry group | Frequency | 1 in |
|---|---|---|
| African / African-Americangrpmax | 0.00133% | 74,934 |
| European (non-Finnish) | 0.000339% | 294,996 |
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
ClinGen expert panel — ENIGMA BRCA1 and BRCA2 VCEP
Uncertain Significance for BRCA2-related cancer predisposition. Applied ACMG criteria (verbatim):
PS3 PP3
Curation rationale (ClinGen, verbatim)
The c.7871A>G variant in BRCA2 is a missense variant predicted to cause substitution of Tyrosine by Cysteine at amino acid 2624 (p.(Tyr2624Cys)). This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). Reported by three calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs:33609447, 39779857, 39779848) (PS3 met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.44, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. A SpliceAI score of 0.01 predicts no impact on splicing (score threshold <0.10) (PP3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 1.76 (based on Co-occurrence LR=1.1; Family History LR=1.6), which is above the ENIGMA BRCA1/2 VCEP threshold for BP5 (>0.48) and below PP4 (<2.08) (BP5 and PP4 not met; PMIDs: 31853058, 31131967). In summary, this variant meets the criteria to be classified as a Variant of uncertain significance for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PS3, PP3).
ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.
Variant & gene context
- Gene
- BRCA2
- Protein
- p.Tyr2624Cys
- Coding
- c.7871A>G
- MANE Select
- NM_000059
- dbSNP
- rs431825358
- Type
- single nucleotide variant
- Location
- chr13:32362588 (GRCh38)
- Gene constraint
- LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
- Residue 2624
- the 'interaction with sem1' region
Disease context
BRCA2-related cancer predisposition — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: hereditary breast ovarian cancer syndromebreast-ovarian cancer, familial, susceptibility to, 2hereditary neoplastic syndromehereditary breast carcinoma
Similar variants
- BRCA2 p.Tyr2624Ter Pathogenic ★★★ same residue
- BRCA2 p.Tyr2624= Likely benign ★★★ same residue
- BRCA2 p.Tyr2624His Uncertain significance ★★ ⚠ same residue
- BRCA2 p.Tyr2624Asp Pathogenic ★ same residue
- BRCA2 p.Tyr2624_Arg2625delinsTer Pathogenic ★★★ same residue
- BRCA2 p.Tyr2624fs Pathogenic ★ same residue
- BRCA2 c.316+1G>T Pathogenic ★★★ same condition
- BRCA2 c.316+2T>C Pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-tyr2624cys (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown